<https://helda.helsinki.fi>

The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation

Poire, Xavier

2020-03

Poire , X , Labopin , M , Polge , E , Volin , L , Finke , J , Ganser , A , Blaise , D , Yakoub-Agha , I , Beelen , D , Forcade , E , Lioure , B , Socie , G , Niederwieser , D , Labussiere-Wallet , H , Maertens , J , Cornelissen , J , Craddock , C , Mohty , M , Esteve , J & Nagler , A 2020 , ' The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation ' , American Journal of Hematology , vol. 95 , no. 3 , pp. 282-294 . <https://doi.org/10.1002/ajh.25714>

<http://hdl.handle.net/10138/328474>

<https://doi.org/10.1002/ajh.25714>

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation.

Xavier Poiré¹, Myriam Labopin^{2,3,4,5}, Emmanuelle Polge^{2,3,4,5}, Liisa Volin⁶, Jürgen Finke⁷, Arnold Ganser⁸, Didier Blaise⁹, Ibrahim Yakoub-Agha¹⁰, Dietrich Beelen¹¹, Edouard Forcade¹², Bruno Lioure¹³, Gérard Socié¹⁴, Dietger Niederwieser¹⁵, Hélène Labussière-Wallet¹⁶, Johan Maertens¹⁷, Jan Cornelissen¹⁸, Charles Craddock¹⁹, Mohamad Mohty^{2,3,4,5,*}, Jordi Esteve^{20,*}, Arnon Nagler^{2,21,*}.

Affiliations;

¹Section of Hematology, Cliniques Universitaires St-Luc, Brussels, Belgium;

²Acute Leukemia Working Party of the EBMT;

³Sorbonne université, Paris, France;

⁴INSERM UMR 938, Paris, France;

⁵Service d'Hématologie, Hôpital Saint-Antoine, Paris, France;

⁶HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland;

⁷Department of Medicine-Hematology-Oncology, University of Freiburg, Freiburg, Germany;

⁸Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;

⁹Institut Paoli Calmette, Programme de Transplantation&Thérapie Cellulaire, Marseille, France;

¹⁰CHU de Lille, LIRIC INSERM U995, Université Lille2, Lille, France;

¹¹Department of Bone Marrow Transplantation, University Hospital, Essen, Germany;

¹²CHU Bordeaux, Hôpital Haut-Leveque, Pessac, France;

¹³Nouvel Hôpital Civil, Strasbourg, France;

¹⁴Department of Hematology, Bone Marrow Transplantation, Hôpital Saint-Louis, Paris, France;

¹⁵Division of Hematology, Oncology and Hemostasiology, University Hospital Leipzig, Leipzig, Germany;

¹⁶Service d'Hématologie, Centre Hospitalier Lyon Sud, Lyon, France;

¹⁷University Hospital Gasthuisberg, Leuven, Belgium;

¹⁸Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;

¹⁹Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom;

²⁰Hematology department, Hospital Clinic, IDIBAPS, Josep Carreras Leukemia Research Institute, Barcelona, Spain;

²¹Chaim Sheba Medical Center, Tel-Hashomer, Israel.

* The three last authors contribute equally to this manuscript.

Running title; Allogeneic transplantation in -7/7q- AML.

Key words; acute myeloid leukemia, allogeneic stem cell transplantation, cytogenetics, monosomy 7, deletion 7q, survival.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ajh.25714

Conflict of interest statements; None of the authors have any conflict of interest with the work presented in this manuscript.

Corresponding author;

Xavier Poiré, MD, PhD

Section of Hematology,

Department of Medicine

Cliniques Universitaires Saint-Luc

10, avenue Hippocrate

1200 Brussels

BELGIUM

Phone: + 32 2 764 18 71

Fax: + 32 2 764 89 59

e-mail: Xavier.Poire@uclouvain.be

Abstract; 241 words.

Text; 4,037 words.

Figures and Tables; 2 figures and 4 tables.

Supplemental material; 2 figures and 1 table.

References; 62.

Abstract

Monosomy 7 or deletion 7q (-7/7q-) is the most frequent adverse cytogenetic features reported in acute myeloid leukemia (AML) and is a common indication for allogeneic stem cell transplantation (SCT). Nevertheless, -7/7q- occurs frequently with other high-risk cytogenetic abnormalities such as complex karyotype (CK), monosomal karyotype (MK), monosomy 5 or deletion 5q (-5/5q-), 17p abnormalities (abn(17p)) or inversion of chromosome 3 (inv(3)), the presence of which may influence the outcomes after SCT.

A total of 1,109 patients has been allocated to this study. Two-year probability of leukemia-free survival (LFS) and overall survival (OS) were 30% and 36%, respectively. Two-year probability of non-relapse mortality (NRM) was 20%. We defined 5 different cytogenetic subgroups: the “-7/7q- ± CK group- designated group1”, the “MK group-designated group 2”, the “-5/5q- group- designated group 3”, the ‘abn(17p) group- designated group 4” and the “inv(3) group- designated group 5”. The 2-year probability of LFS in first remission was 48% for group 1, 36.4% for group 2, 28.4% for group 3, 19.1% for group 4 and 17.3% for group 5,

respectively ($p < 0.001$). Multivariate analysis confirmed those significant differences across groups.

SCT in -7/7q- AML provides durable response in one third of the patients. The presence of -7/7q- with or without CK in the absence of MK, abn(17p) or inv(3) is associated with a better survival after SCT. On the contrary, addition of MK, -5/5q-, abn(17p) or inv(3) identifies a subgroup of patients with poor prognosis even after SCT.

Introduction

Allogeneic stem cell transplantation (SCT) still remains the best consolidation strategy in patients with acute myeloid leukemia (AML) harbouring adverse cytogenetic features (1-5). These poor-risk cytogenetic events confer resistance to standard chemotherapy (6), and only a potent graft-versus-leukemia (GvL) effect arising from SCT may offer an opportunity of cure (7). The clinical benefit of SCT in high-risk AML has been well demonstrated (8-10). However, high-risk AML encompass a very heterogeneous group of disease categories including different cytogenetic abnormalities, mutational events or refractory disease (2, 11) and the benefit of SCT in each of these specific settings has been showed to be significantly different (12). Monosomy 7 or deletion 7q has been recognized for many years as a high-risk cytogenetic

Accepted Article

feature in AML and it is the most frequent adverse abnormality reported (4). It is frequently associated with therapy-related AML, occurring after exposure to alkylating agents (13). It is also frequently co-occurring with other adverse cytogenetic features such as complex karyotype (CK), monosomy 5 or deletion 5q (-5/5q-) or inversion of chromosome 3 (inv(3)) (3). Consequently, it remains a very common indication for SCT and its specific outcome in that setting has never been thoroughly studied.

Monosomal karyotype (MK) has been associated with a very poor outcome with an estimated 4-year survival rate of 4% (14, 15). Within MK, the presence of monosomy 7 alone did not show any independent impact on survival (14, 16). However, in the transplant setting, a retrospective study from the EBMT addressing SCT for MK AML showed that monosomy 7 retained a significant impact on outcomes (17). We recently reported the outcome of 125 patients with AML and 17p abnormalities (abn(17p)) transplanted in first remission. Interestingly, the co-occurrence of -7 without -5/5q- translated into a much better survival than the frequent combination of -5/5q- and abn(17p) (18), which raises the questions of a potential better outcome after SCT for patients with -7/7q- and the influence of concomitant cytogenetic abnormalities. Subsequently, we studied a cohort of 501 patients with -5/5q- in which we were not able to demonstrate any impact of -7/7q- on outcomes after SCT (19). We therefore conducted a retrospective study focusing on patients with AML with -7/7q- undergoing SCT and we analyzed the impact of frequent co-occurring cytogenetic abnormalities such as CK, MK, -5/5q-, abn(17p) and inv(3)/t(3;3).

Methods

Patient selection and data collection

This is a retrospective registry-based analysis on behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). The EBMT is a non-profit, scientific society representing more than 600 transplant centers mainly in Europe that are required to report all consecutive stem cell transplantations and their follow-up once a year. Data are entered, managed and maintained in a central database with internet access; each EBMT center is represented in this database. Audits are routinely performed to determine the accuracy of the data. Patients or legal guardian provide informed consent authorizing the use of their personal information for research purposes. The study was approved by the ALWP review board.

Eligibility criteria for the study included all patients ≥ 18 years and with de novo or secondary AML transplanted between 1 January 2000 and 31 December 2016 from an HLA-matched sibling (MSD) or a fully-matched (10/10) unrelated donor (MUD). Patients undergoing second transplantation as well as patients having a haplo-identical or cord-blood transplantation were excluded. We further selected patients harboring $-7/7q-$ and having a full karyotype report within the database in order to study the prognostic impact of additional cytogenetic features. A total of 1,109 patients from 179 centers met the study inclusion criteria and were selected for further analysis. Myeloablative conditioning (MAC) was defined as a regimen containing either total body irradiation (TBI) with a dose greater than 6 Gy, a total dose of oral busulfan (Bu) greater than 8 mg/kg, or a total dose of intravenous Bu greater than 6.4 mg/kg. All other regimens were defined as reduced intensity conditioning (RIC) (20).

The following variables were selected and included in the analysis: year of transplantation, age, gender, white blood cell count (WBC) at diagnosis, de novo or secondary AML condition,

Accepted Article

number of induction courses to achieve CR, status at transplantation, time from diagnosis to SCT, type of conditioning regimen, use of TBI, in vivo T-cell depletion (including both anti-thymocyte globulins and alemtuzumab), cytomegalovirus (CMV) status of donor and recipient, donor type, source of stem cells, Karnofsky performance status at transplantation, engraftment, presence of acute and chronic graft-versus-host disease (GvHD), grade of acute GvHD, severity of chronic GVHD. Secondary AML has been defined by AML with previous diagnosis of myelodysplastic syndromes or myeloproliferative neoplasms or AML secondary to cytotoxic therapies. For the analysis of additional cytogenetic abnormalities, we included in our analysis the presence of abnormalities of 3q26 (e.g., inv(3)(q21q26) or t(3;3)(q21;q26)), abnormalities leading to loss of chromosome 17p (abn(17p)), monosomy 5 or deletion 5q, monosomal karyotype (MK) and complex karyotype (CK) classified according to the cytogenetic status by Medical Research Council UK criteria (3).

Statistical analysis and endpoints definitions

Primary endpoint was LFS. Secondary endpoints included relapse incidence (RI), non-relapse mortality (NRM), overall survival (OS), acute and chronic GvHD, and refined GvHD-free/relapse-free survival (GRFS). All outcomes were measured from the time of transplant. LFS was defined as survival without relapse; patients alive without relapse were censored at the time of last contact. OS was based on death from any cause. NRM was defined as death without previous relapse. GRFS was defined as survival without grade 3-4 acute GvHD, extensive chronic GvHD, relapse or death(21). Surviving patients were censored at the time of last contact. The probabilities of OS, LFS, and GRFS were calculated by the Kaplan-Meier test,

and those of acute and chronic GVHD, NRM, and relapse by the cumulative incidence estimator to accommodate competing risks. For NRM, relapse was the competing risk, and for relapse, the competing risk was NRM. For acute and chronic GvHD, death without the event and relapse were the competing risks.

For all univariate analyses, continuous variables were categorized and the median value was used as a cut-off point. A Cox proportional hazards model was used for multivariate regression including factors associated with LFS in univariate analysis and individual cytogenetics abnormalities. Finally, we defined five groups according to the complexity of the karyotype, the presence of a MK and the presence or not of individual cytogenetic abnormalities significantly associated with the outcome. Patient, disease and transplant-related characteristics for the five groups were compared by using χ^2 statistics for categorical variables and the Kruskal-Wallis test for continuous variables. Factors differing in distribution between the groups or conceptually important were included in the final Cox model. Proportional hazards assumptions were checked systematically using the Grambsch-Therneau residual-based test. All interactions between cytogenetics groups and other covariates were tested. Results were expressed as hazard ratio (HR) with 95% confidence interval (CI). Statistical analyses were performed with SPSS 24.0 (SPSS Inc, Chicago, IL, USA) and R 3.4.1 (R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.)

Results

Patients' characteristics

Table 1 summarize patients' characteristics of the entire population as well as separately for those harbouring 7q- or -7. A total of 1,109 patients met the inclusion criteria and were included in the present analysis. Median follow-up using the reverse Kaplan-Meier was 59 months (interquartile range, 26-106). Median age at SCT was 52 years (range, 18-76). The main MAC regimens were the combination of cyclophosphamide with TBI (33%) or cyclophosphamide with busulfan (32%), and the two most frequent RIC regimens were fludarabine and busulfan (32%) followed by fludarabine and low dose TBI (18%). For GvHD prophylaxis, patients mostly received the combination of cyclosporine with methotrexate (42%) or cyclosporine with mycophenolate mofetil (27%). As to cytogenetics, karyotype from 468 patients (52%) did not contain additional studied cytogenetic abnormalities, whereas 532 (48%) and 425 (38%) patients fulfilled criteria for MK and CK AML, respectively, in addition to -7/7q-. Both categories presented a great overlap, with 338 patients meeting characteristics of both MK and CK. The presence of -5/5q- was seen in 240 patients (22%), while abn(17p) and inv(3) were present in 128 (12%) and 111 (10%) patients, respectively. When looking separately to patients with 7q- or -7, we observed significantly more MK and inv(3) in -7 patients. All these cytogenetic categories presented a great overlap, as illustrated in Figure 1.

Transplantation outcome by univariate analysis: relapse incidence, non-relapse mortality, leukemia-free survival, overall survival, cause of death, and graft-versus-host disease in the entire cohort.

The 2-year cumulative incidence of relapse in the overall series was 49.7% [95% CI: 46.6-52.7] (see supplemental Figure 1A). In univariate analysis, RI was significantly associated with

Accepted Article

disease status, being higher for patients transplanted in subsequent remission and those with active disease at the time SCT. Transplant from MSD was also followed by higher RI than SCT from MUD. Age, secondary AML, performance status, stem cell source, conditioning intensity and in vivo TCD were not associated with RI. All additional cytogenetic abnormalities tested were significantly associated with increased RI as detailed in Table 2.

The 2-year probability of NRM was 20.1% [95% CI: 17.7-22.6] (see supplemental Figure 1B). The variables significantly associated with reduced NRM were SCT from MSD, younger donor's age, being in CR1 at the time of SCT, de novo AML compared to secondary AML and a better performance status at the time of SCT. All other variables, including additional cytogenetic abnormalities were not associated with mortality as shown in Table 2 for additional cytogenetic abnormalities.

The overall 2-year probability of LFS was 30.2% [95% CI: 27.3-33] (see supplemental Figure 1C). In univariate analysis, we found a significant better LFS with the following variables; SCT performed after 2009, being in CR1 at the time of SCT versus subsequent disease status, de novo AML compared to secondary AML and a better performance status at the time of SCT. In contrast, donor type, age, stem cell source and conditioning intensity did not have any impact on LFS. Finally, every studied additional cytogenetic abnormality was associated with worse LFS as detailed in Table 2.

Two-year OS was 36.4% [95% CI: 33.4-39.4] (see supplemental Figure 1D). In univariate analysis, a worse OS was observed in patients transplanted in subsequent disease status compared to CR1, with secondary AML, with a worse KPS and among those male recipients having a female donor. In contrast, age, donor type, year of SCT, stem cell source and conditioning intensity did not have an impact on OS. As for LFS, additional cytogenetic adverse features were all associated with decreased OS as shown in Table 2. The main causes of death were disease-related followed by infections and GvHD.

The 100-day cumulative incidence of grade II-IV and III-IV acute GvHD was 30.7% [95% CI: 27.9-33.5] and 11.3% [95% CI: 9.5-13.3], respectively. The 2-year cumulative incidence of total and extensive chronic GvHD was 30.9% [95% CI: 28-33.8] and 15.8% [95% CI: 13.6-18.2], respectively. The 2-year probability of GRFS was 20.8% [95% CI: 18.3-23.3]. A higher cumulative incidence of grade II-IV acute GvHD was associated with MUD, younger age, active disease at the time of SCT and patient's CMV negativity. In addition, the presence of CK was associated with lower incidence of acute GvHD (26.4% [95% CI: 22.2-30.8] as compared to 33.3% [95% CI: 29.7-37] in patients without CK, $p=0.03$). A lower incidence of chronic GvHD was associated with active disease at the time of SCT. Regarding additional adverse cytogenetic features, presence of MK, $abn(17p)$ and $inv(3)$ were all associated with less chronic GvHD. In vivo TCD was associated with a reduced incidence of extensive chronic GvHD. A significant better GRFS was observed among patients transplanted after 2009, patients in CR1, with de novo AML compared to secondary AML and among those with better KPS at the time of SCT. A female donor to male recipient translated also into worse GRFS.

Additionally, in vivo TCD was significantly associated with better GRFS. Finally, all studied additional cytogenetic abnormalities correlated significantly with worse GRFS as detailed in Table 2.

Prognostic factors by multivariate analysis in the entire population.

Active disease at the time of SCT remained the strongest predictive factor for worse RI, NRM, LFS, OS and GRFS in multivariate analysis as shown in Table 3. Subsequent remissions were associated with a decreased LFS, OS and GRFS, and with an increased NRM. Of note, age lost any significant impact on outcomes in our multivariate model. A better performance status correlated strongly with better LFS, OS and GRFS due to significantly lower NRM. Secondary AML was also associated with worse LFS, OS and GRFS, as well as with increased NRM, but had no impact on RI. The use of MUD correlated with higher NRM, which did not translate into worse LFS and OS. Use of RIC regimens was associated with worse LFS than MAC regimens. CMV status of the donor and/or the recipient lost any impact in multivariate analysis. As for additional adverse cytogenetic abnormalities, none of them impacted NRM in our Cox model. CK was not significantly associated with RI, LFS, OS and GRFS while MK showed a significantly increased RI and decreased LFS and GRFS. -5/5q-, abn(17p) and inv(3) were all associated with increased RI and worse LFS, OS and GRFS.

Outcomes by cytogenetic subgroups.

Accepted Article

In order to elucidate the impact of additional cytogenetic abnormalities on outcomes of patients with AML and -7/7q- after transplantation, we defined 5 different subgroups within our entire cohort in a hierarchical manner. Due to the overlap between all additional cytogenetic abnormalities, our hierarchy was based on the statistical weight of CK, MK, -5/5q-, abn(17p) and inv(3) resulting from our previous multivariate analysis, and on their capability to distinguish biologically and clinically meaningful cytogenetic categories. The “-7/7q- ± CK group” included 523 -7/7q- patients with or without CK but in the absence of MK, -5/5q-, abn(17p) or inv(3). The “MK group” contained 199 patients fulfilling the definition of MK in the absence of -5/5q-, abn(17p) or inv(3). The “-5/5q- group” comprised 151 -7/7q- patients in combination with -5/5q- with the exception of abn(17p) and inv(3). In the “abn(17p) group”, 125 patients harbored abn(17p) in addition to -7/7q- excluding 3 patients with inv(3). Finally, the “inv(3) group” encompassed 111 patients to the combination of -7/7q- with inv(3) regardless of the presence of other adverse cytogenetic features. As shown in the supplemental material, there were a few differences in baseline characteristics between those 5 groups. Patients in the “inv(3) group” were younger and more frequently transplanted with active disease. When we included those 5 groups into a Cox model, we found that the “MK”, “-5/5q-”, “abn(17p)” and “inv(3)” groups were all associated with a significant higher RI and decreased LFS and OS compared to both the “7q- and -7 ± CK” groups as shown in Table 4.

As disease status at the time of SCT is a strong and well-established prognostic factor of outcomes after SCT, we subsequently decided to focus on the 702 patients transplanted in CR1 as illustrated in Figure 2. The 2-year cumulative incidence of relapse was 36.7% for the “-7/7q-

Accepted Article

± CK group”, 47.8% for the “MK group”, 51% for the “-5/5q- group”, 62.9% and 68.4% for the “inv(3) group” ($p<0.0001$, Figure 2A), which translated into a 2-year probability of LFS of 48%, 36.4%, 28.4%, 19.1% and 17.3% for the “-7/7q- ± CK”, “MK”, “-5/5q-“, “abn(17p)” and “inv(3)” groups, respectively ($p<0.0001$, Figure 2C). The 2-year NRM was similar across our 5 cytogenetic groups ($p=0.69$, Figure 2B) but the 2-year probability of OS was significantly influenced by subgroups, being 58.2%, 44.6%, 36%, 18.7% and 21.8% for the “-7/7q- ± CK”, “MK”, “-5/5q-“, “abn(17p)” and “inv(3)” groups, respectively ($p<0.0001$, Figure 2D). The 2-year probabilities of GRFS were 36.6% [95% CI: 31.1-42.1] for the “-7/7q- ± CK” group, 20.8% [95% CI: 13-28.5] for the “MK” group, 17.2% [95% CI: 9.2-25.2] for the “-5/5q-“ group, 7.3% [95% CI: 1.5-13.2] for the “abn(17p)” group and 13.1% [95% CI: 3.4-22.8] for the “inv(3)” group ($p<0.0001$). When studying separately deletion 7q from monosomy 7 within the “-7/7q- ± CK group”, we found in multivariate analysis that monosomy 7 showed a significant increase in RI, which translated into worse LFS, without impacting OS or GRFS (Table 4 and see supplemental Figure 2).

Discussion

-7/7q- is the most frequent autosomal monosomy reported in AML (22, 23) and is consistently associated with a very bad prognosis after chemotherapy alone (3, 24). As other high-risk AML, SCT appears as the best consolidation strategy with prolonged disease-free survival in about 40% of the patients (1, 8, 9, 25). However, we obtained 2-year LFS and OS of 30% and 36%, respectively in our large cohort, which remains worse than the expected survival for high-risk AML after SCT (9). Patients transplanted in CR1 could enjoyed a better 2-year LFS of 37%. The poorer results observed in our population could either be explained by -7/7q- which remains a well-known adverse feature in AML, or by other bad risk factors included in this cohort. We found the usual prognostic factors associated with worse outcomes such as active disease at SCT (8) and bad performance status (26). We also found that sAML was significantly associated with increased NRM and decreased OS as previously described (27, 28), mainly due to the excess of toxicity from previous chemotherapy found in therapy-related AML. In contrast, we did not find any impact of age in multivariate analysis (1, 29). Finally, a RIC

regimen was associated with worse LFS without impacting OS, despite the chemo-refractory properties of AML with MK and/or TP53 dysfunction included in this cohort (30, 31).

-7/7q- is the most frequent cytogenetic feature reported as sole abnormality (23), which is well illustrated within our population with 42% of the patients harboring -7/7q- without CK, MK, -5/5q-, abn(17p) and inv(3). As suggested by our previous dataset (18), we hypothesized that the prognosis of our cohort would be dictated by the presence of additional adverse cytogenetic abnormalities. While CK did not show an impact on outcomes in multivariate analysis, we found a significant worse survival in patients harboring MK, -5/5q-, abn(17p) and inv(3). As illustrated by our Venn diagram, most of those abnormalities are combined with each other, making it difficult to avoid the confounding effect of overlapping cytogenetic categories. We therefore decided to define 5 different groups based on a hierarchical prognostic effect of MK, -5/5q-, abn(17p) and inv(3). This cytogenetic stratification allowed us to confirm the strong negative impact of MK, -5/5q-, abn(17p) and inv(3). Patients harboring -7/7q- in combination or not with additional cytogenetic abnormalities with the exception of MK, -5/5q-, abn(17p) and inv(3) showed a 2-year probability of LFS of 48% if transplanted in CR1, better than the expected survival after SCT in high-risk AML (9). The “MK” and “-5/5q-” groups both showed a significantly decreased survival compared to the “-7/7q- ± CK” group. Outcomes for the “-5/5q-” group appeared somehow worse than for “MK” group. Similarly, Middeke et al. showed in a smaller cohort that -5/5q- led to worse outcome than MK after SCT, but in contrast to their observations (32), we still found a negative impact of MK on outcomes after SCT as shown by others (17, 33-35). We may speculate that the worse results observed with -5/5q- might be

related to the higher prevalence of *TP53* mutations in this entity (36, 37), but we cannot further analyze this hypothesis in the context of a registry-based study. One of the most important limitations of our study is the lack of molecular data within the registry, which are now routinely available. Our hierarchical stratification may indeed reflect the increasing frequency of *TP53* mutations across the groups as previously observed (38, 39). Our “abn(17p)” group translated into a 2-year probability of LFS of only 19% if transplanted in CR1, which is worse than previously published data (18, 40). These worse results might be related to the presence of 66% -5/5q- within the “abn(17p)” group, which supports our previous observation of the deleterious effect of the combination of -5/5q- and abn(17p) on outcomes after SCT (18). To further support the negative combinatorial impact of -5/5q- and abn(17p), we subsequently studied separately -5/5q-, abn(17p) and the combination of -5/5q- with abn(17p). We confirmed that -5/5q- with abn(17p) led to worse survival than each abnormality on its own (data not shown). Regarding inv(3), we showed a 2-year LFS of 17% in patients transplanted in CR1. Our survival appears inferior to the 2-year LFS of 24% reported recently by Halaburda et al (41). -7/7q- is the most frequent additional cytogenetic abnormality found in inv(3) AML (41-44). A negative impact of the combination of inv(3) and -7/7q- has been suggested in univariate analysis in previous reports, but not confirmed in multivariate analysis (41, 44). However, one or more haploinsufficient tumor suppressor genes on the long arm of chromosome 7, such as CUX1, may cooperate with inv(3) to lead to a highly refractory AML clone (45, 46). Our observations support this additive effect of -7/7q- and inv(3) on outcomes after SCT. Finally, a better prognosis for 7q- than -7 has been suggested in several studies, mainly performed in patients with MDS (47, 48), while others did not show significant differences in survival (49, 50). Our

observations support some different impacts from both -7 and 7q-, which remained significant in multivariate analysis only with regard to the relapse incidence.

Our cohort included the most frequent adverse cytogenetic features reported in AML and we have clearly shown that they are not equal in terms of the expected benefit from SCT. If -7/7q- AML with or without CK demonstrated significant improved survival after SCT, the benefit of SCT is much more limited with the addition of MK, -5/5q-, abn(17p) and inv(3). Patients harboring MK, -5/5q- and abn(17p) have a high frequency of *TP53* mutations (36-38, 51, 52), which is known to be associated with chemo-resistance and lower sensitivity to a graft-versus-leukemia effect (18). The first goal in those high-risk patients is to bring them into remission (39) with *TP53*-independent drugs such as decitabine (53) or venetoclax (54, 55). However, even if transplanted in CR1, the benefit of SCT remains questionable, especially in those harboring the combination of -5/5q- with abn(17p) or the presence of inv(3). The very short median time to relapse after SCT forces us to integrate early post-transplant interventions such as hypomethylating agents (56-58), prophylactic donor leukocyte infusions (59, 60) or combination of both. Another limitation of our study is the lack of information about post-SCT interventions within the registry. However, such strategies should be further studied, especially in specific cytogenetic subgroups such as the combination of -5/5q- with abn(17p). Patients harboring -7/7q- alone or in combination with inv(3) show frequent association with *RAS* pathway mutations (22, 42, 45), which could be targeted by small molecule inhibitors (61, 62). However, the best strategy to handle those very high-risk AML after SCT is still to be

discovered and efforts have to be made in the next future to study novel therapeutic interventions with or without SCT.

In conclusions, we have reported a very large population of 1109 AML with -7/7q- after SCT, including the most common adverse cytogenetic features such as CK, MK, -5/5q-, abn(17p) and inv(3). A transplant strategy in our cohort led to a 2-year survival in about 30% of the patients. One of the largest limitations in this study might be the lack of centralized cytogenetic analysis and the selection of patients with an available full cytogenetic report, an essential requirement for the proposed analysis. Active disease at the time of SCT remains the strongest prognostic factor of worse survival and cautions have to be made when bringing those patients to SCT. Novel therapeutic pre-transplant strategies must be developed to increase the proportion of patients into remission before SCT. The main finding of our study is that the benefit of SCT remains highly dependent on the presence of other adverse features such as MK, -5/5q-, abn(17p) and inv(3). The benefit of SCT appears debatable particularly in patients harboring abn(17p) and inv(3) with the current standard approach, especially if not in CR1 at the time of SCT. The decision of SCT for those patients should be integrate with the development of pre-transplant and post-transplant pharmacological and immunological maneuvers to sustain response. Early withdrawal of immunosuppression, maintenance therapy and DLI should be considered but inclusion in clinical trials may help us to better define the best strategies in the future.

References

- Accepted Article
1. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? *Blood*. 2007;109(9):3658-66.
 2. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129(4):424-47.
 3. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. *Blood*. 2010;116(3):354-65.
 4. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. *Blood*. 1998;92(7):2322-33.
 5. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. *JAMA*. 2009;301(22):2349-61.
 6. Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. *Genes Chromosomes Cancer*. 2005;43(3):227-38.
 7. Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. *Leukemia*. 2012;26(12):2462-8.
 8. Schlenk RF, Dohner K, Mack S, Stoppel M, Kiraly F, Gotze K, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. *J Clin Oncol*. 2010;28(30):4642-8.
 9. Stelljes M, Beelen DW, Braess J, Sauerland MC, Heinecke A, Berning B, et al. Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. *Haematologica*. 2011;96(7):972-9.
 10. Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, et al. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. *Lancet Haematol*. 2015;2(10):e427-36.
 11. Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. *Bone Marrow Transplant*. 2015;50(8):1037-56.

- Accepted Article
12. Canaani J, Labopin M, Itala-Remes M, Blaise D, Socie G, Forcade E, et al. Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. *Leukemia*. 2019.
 13. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. *Blood*. 2003;102(1):43-52.
 14. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. *J Clin Oncol*. 2008;26(29):4791-7.
 15. Haferlach C, Alpermann T, Schnittger S, Kern W, Chromik J, Schmid C, et al. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. *Blood*. 2012;119(9):2122-5.
 16. Jang JE, Min YH, Yoon J, Kim I, Lee JH, Jung CW, et al. Single monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotype. *Blood Cancer J*. 2015;5:e358.
 17. Brands-Nijenhuis AV, Labopin M, Schouten HC, Volin L, Socie G, Cornelissen JJ, et al. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT. *Haematologica*. 2016;101(2):248-55.
 18. Poire X, Labopin M, Maertens J, Yakoub-Agha I, Blaise D, Ifrah N, et al. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). *J Hematol Oncol*. 2017;10(1):20.
 19. Poire X, Labopin M, Polge E, Forcade E, Ganser A, Volin L, et al. Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. *Haematologica*. 2019.
 20. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. *Biol Blood Marrow Transplant*. 2009;15(12):1628-33.
 21. Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. *Bone Marrow Transplant*. 2016;51(4):610-1.
 22. Eisfeld AK, Kohlschmidt J, Mrozek K, Volinia S, Blachly JS, Nicolet D, et al. Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. *Cancer Res*. 2017;77(1):207-18.
 23. Raza S, TaherNazerHussain F, Patnaik M, Knudson R, Van Dyke D, Tefferi A. Autosomal monosomies among 24,262 consecutive cytogenetic studies: prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities. *Am J Hematol*. 2011;86(4):353-6.

24. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). *Blood*. 2002;100(13):4325-36.
25. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. *Blood*. 2000;96(13):4075-83.
26. Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. *Cancer*. 2008;112(9):1992-2001.
27. Alam N, Atenafu EG, Kuruvilla J, Uhm J, Lipton JH, Messner HA, et al. Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation. *Bone Marrow Transplant*. 2015;50(9):1180-6.
28. Shin SH, Yahng SA, Yoon JH, Lee SE, Cho BS, Eom KS, et al. Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure. *Bone Marrow Transplant*. 2013;48(5):678-83.
29. Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. *J Clin Oncol*. 2014;32(29):3249-56.
30. Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagensohn MD, et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. *N Engl J Med*. 2017;376(6):536-47.
31. Poire X, Labopin M, Cornelissen JJ, Volin L, Richard Espiga C, Veelken JH, et al. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT). *Am J Hematol*. 2015;90(8):719-24.
32. Middeke JM, Beelen D, Stadler M, Gohring G, Schlegelberger B, Baurmann H, et al. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abn(17p) and -5/5q. *Blood*. 2012;120(12):2521-8.
33. Breems DA, Van Putten WL, Lowenberg B. The impact of abn(17p) and monosomy -5/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia. *Blood*. 2013;121(15):3056-7.
34. Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Passweg JR, Pabst T, et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. *J Clin Oncol*. 2012;30(17):2140-6.
35. Pasquini MC, Zhang MJ, Medeiros BC, Armand P, Hu ZH, Nishihori T, et al. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. *Biol Blood Marrow Transplant*. 2016;22(2):248-57.
36. Castro PD, Liang JC, Nagarajan L. Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms. *Blood*. 2000;95(6):2138-43.

37. Stoddart A, Fernald AA, Wang J, Davis EM, Karrison T, Anastasi J, et al. Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. *Blood*. 2014;123(7):1069-78.
38. Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. *Leukemia*. 2019;33(7):1747-58.
39. Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. *Blood*. 2012;119(9):2114-21.
40. Middeke JM, Fang M, Cornelissen JJ, Mohr B, Appelbaum FR, Stadler M, et al. Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. *Blood*. 2014;123(19):2960-7.
41. Halaburda K, Labopin M, Houhou M, Niederwieser D, Finke J, Volin L, et al. AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. *Bone Marrow Transplant*. 2018;53(6):683-91.
42. Lugthart S, Groschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. *J Clin Oncol*. 2010;28(24):3890-8.
43. McNerney ME, Brown CD, Peterson AL, Banerjee M, Larson RA, Anastasi J, et al. The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q). *Br J Haematol*. 2014;166(4):550-6.
44. Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. *Haematologica*. 2014;99(5):821-9.
45. Groschel S, Sanders MA, Hoogenboezem R, Zeilemaker A, Havermans M, Erpelinck C, et al. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. *Blood*. 2015;125(1):133-9.
46. McNerney ME, Brown CD, Wang X, Bartom ET, Karmakar S, Bandlamudi C, et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. *Blood*. 2013;121(6):975-83.
47. Cordoba I, Gonzalez-Porras JR, Nomdedeu B, Luno E, de Paz R, Such E, et al. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. *Cancer*. 2012;118(1):127-33.
48. Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. *J Clin Oncol*. 2012;30(8):820-9.
49. Hussain FT, Nguyen EP, Raza S, Knudson R, Pardani A, Hanson CA, et al. Sole abnormalities of chromosome 7 in myeloid malignancies: spectrum, histopathologic correlates, and prognostic implications. *Am J Hematol*. 2012;87(7):684-6.

50. Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. *Blood*. 2012;119(25):6109-17.
51. Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. *Br J Haematol*. 2013;160(5):660-72.
52. Middeke JM, Herold S, Rucker-Braun E, Berdel WE, Stelljes M, Kaufmann M, et al. TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. *Br J Haematol*. 2016;172(6):914-22.
53. Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. *N Engl J Med*. 2016;375(21):2023-36.
54. DiNardo C.D. PDA, Jonas B.A., Konopleva M, Pullarkart V., Wei A., Kantarjian H.M., Pigneux A., Recher C., Seymour J., Dunbar M., Xu T., Mabry M., Potluri J., Pratz K., and Letai A. Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia. *Blood*. 2017;130(Suppl 1):2628.
55. Wei A, Strickland S.A., Roboz G.J., Hou J-Z, Fiedler W, Lin T.L., Walter R.B., Enjenti A, Chyla B, Popovic R, Fakouhi K, Shah P, , Dunbar M., Xu T., Mabry M. and Hayslip J. Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes. *Blood*. 2017;130(Suppl 1):890.
56. El-Cheikh J, Massoud R, Fares E, Kreidieh N, Mahfouz R, Charafeddine M, et al. Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT. *Bone Marrow Transplant*. 2017;52(6):918-21.
57. Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, et al. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. *Biol Blood Marrow Transplant*. 2015;21(10):1761-9.
58. Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. *Int J Hematol*. 2018;107(2):138-50.
59. Tsirigotis P, Byrne M, Schmid C, Baron F, Ciceri F, Esteve J, et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. *Bone Marrow Transplant*. 2016;51(11):1431-8.
60. Yafour N, Beckerich F, Bulabois CE, Chevallier P, Daguindau E, Dumesnil C, et al. How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome. *Curr Res Transl Med*. 2017;65(2):65-9.
61. Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, et al. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. *Cancer*. 2016;122(12):1871-9.
62. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. *Clin Cancer Res*. 2014;20(2):490-8.

Figures' legend

Figure 1: Additional cytogenetic abnormalities.

A total of 468 patients harboured -7/7q- without additional adverse cytogenetic features. The vast majority of patients showed MK (48%) or CK (38%) in combination with -7/7q-. The presence of -5/5q- was seen in 240 patients (22%), while abn(17p) and inv(3) were present in 128 (12%) and 111 (10%) patients, respectively. The Venn diagram illustrates well that most of those adverse cytogenetic features were not present as a single additional abnormality but rather exist in combination.

Figure 2: Relapse incidence (RI), non-relapse mortality (NRM), leukemia-free survival (LFS) and overall survival (OS) by cytogenetic groups in patients transplanted in first remission.

The 2-year cumulative incidence of relapse was 36.7% [95% CI: 31.3-42.2] for the “-7/7q- ± CK group”, 47.8% [95% CI: 38.3-56.7] for the “MK group”, 51% [95% CI: 40.1-60.9] for the “-5/5q- group”, 62.9% [95% CI: 51.3-72.4] and 68.4% [95% CI: 52.7-79.8] for the “inv(3) group” (p<0.0001) (A) and the 2-year probability of NRM was similar across the 5 groups, reaching 16.4% [95% CI: 13.6-19.3] (p=0.69) (B). The 2-year probability of LFS was 48% [95% CI: 42.3-53.6], 36.4% [95% CI: 27.5-45.4], 28.4% [95% CI: 18.9-37.9], 19.1% [95% CI: 10.4-27.8] and 17.3% [95% CI: 6.5-28.1] for each group, respectively (p<0.0001) (C). The 2-year probability OS was 58.2% [95% CI: 52.6-63.9] for the “-7/7q- ± CK group”, 44.6% [95% CI: 35.2-53.9] for the “MK group”, 36% [95% CI: 25.8-46.3] for the “-5/5q- group”, 18.7% [95% CI: 9.9-27.4] for the “abn(17p) group” and 21.8% [95% CI: 9.8-33.8] for the “inv(3) group” (p<0.0001) (D).

Table 1
Patients' characteristics

	Entire population	7q-	-7	p-value
N	1109	331	778	
Median follow-up (inter-quartile range)	59 months (26-106)	56 months (25-102)	59 months (26-108)	0.45
Median age, years (range)	52 (18-76)	51.9 (18.1-70.8)	52.2 (18-76.1)	0.46
Time from diagnosis to SCT, months (range)	4.9 (0.4-387)	5.1 (1.5-386.8)	4.8 (0.4-280.8)	0.04
Median year of SCT (range)	2009 (2000-2015)	2009 (2000-2015)	2009 (2000-2015)	0.45
Disease status at SCT, N (%)				0.18
CR1	702 (63)	222 (67)	480 (62)	
CR2/CR3	58 (5)	18 (5)	40 (5)	
Active disease	348 (32)	91 (28)	258 (33)	
Secondary AML, N (%)	213 (19)	62 (19)	151 (19)	0.79
Donor type, N (%)				0.04
MSD/MUD	496/613 (45/55)	164/167 (49/50)	332/446 (43/57)	
Patients' gender, N (%)				0.17
M/F	597/511 (54/46)	168/163 (51/49)	332/446 (43/57)	
Female donor to male recipient, N (%)	184 (17)	54 (17)	130 (17)	0.89
KPS $\geq$ 80%, N (%)	966 (93)	297 (96)	669 (92)	0.04
Patient CMV positive, N (%)	685 (64)	215 (67)	470 (62)	0.11
Donor CMV positive, N (%)	523 (49)	155 (49)	368 (49)	0.95
Conditioning intensity, N (%)				0.42
MAC/RIC	549/560 (49/51)	170/161 (51/49)	379/399 (49/51)	
Stem cell source, N (%)				0.03
BM/PB	165/944 (15/85)	61/270 (18/82)	104/674 (13/87)	
In vivo TCD, N (%)	625 (56)	185 (56)	440 (57)	0.84
CK, N (%)	425 (38)	135 (41)	290 (37)	0.27
MK, N (%)	532 (48)	70 (21)	462 (59)	0.001
-5/5q-, N (%)	240 (22)	78 (24)	162 (21)	0.31
abn(17p), N (%)	128 (12)	36 (11)	92 (12)	0.65
inv(3), N (%)	111 (10)	10 (3)	101 (13)	0.001

Abbreviations: SCT: allogeneic stem cell transplantation; N: number; CR1: first remission; CR2: second remission; CR3: third remission; AML: acute myeloid leukemia; MSD: matched sibling donor; MUD: matched unrelated donor; M: male; F: female; KPS: Karnofsky's performance status; CMV: cytomegalovirus; MAC: myeloablative conditioning regimen; RIC: reduced-intensity conditioning regimen; BM: bone marrow; PB: peripheral blood; TCD: T-cell depletion; CK: complex karyotype; MK: monosomal karyotype; -5/5q-: monosomy 5 or deletion 5q; abn(17p): 17p abnormalities; inv(3): inversion of chromosome 3.

Table 2
Univariate analysis of additional cytogenetic abnormalities

	RI		NRM		LFS		OS		GRFS		Grade II-IV aGVHD		cGvHD	
	2y (% 95%CI)	p	2y (% 95%CI)	p	2y (% 95%CI)	p	2y (% 95%CI)	p	2y (% 95%CI)	p	2y (% 95%CI)	p	2y (% 95%CI)	p
CK														
Yes	57 (52-62)	<0.0001	20 (16-24)	0.99	23 (18-27)	<0.0001	27 (22-31)	<0.0001	13 (10-16)	<0.0001	26 (22-31)	0.03	29 (25-34)	0.44
No	45 (41-49)		20 (17-23)		35 (31-39)		42 (38-46)		27 (22-29)		33 (30-37)		32 (28-36)	
MK														
Yes	60 (55-64)	<0.0001	19 (15-22)	0.27	22 (18-26)	<0.0001	27 (23-31)	<0.0001	13 (10-16)	<0.0001	32 (28-36)	0.4	28 (24-32)	0.05
No	41 (37-45)		22 (18-25)		38 (34-42)		45 (41-50)		28 (24-32)		30 (26-34)		34 (30-38)	
Abn(5q)														
Yes	61 (54-67)	<0.0001	20 (15-26)	0.95	19 (14-25)	<0.0001	23 (17-28)	<0.0001	12 (8-16)	<0.0001	29 (23-35)	0.5	29 (23-35)	0.43
No	47 (43-50)		20 (17-23)		33 (30-37)		40 (37-44)		23 (20-26)		31 (28-34)		32 (28-35)	
Inv(3)														
Yes	70 (60-77)	<0.0001	17 (10-25)	0.39	14 (7-20)	<0.0001	20 (12-28)	<0.0001	9 (3-15)	0.0002	37 (28-46)	0.15	20 (12-28)	0.04
No	48 (44-51)		21 (18-23)		32 (29-35)		38 (35-42)		22 (19-25)		30 (27-33)		32 (29-35)	
Abn(17p)														
Yes	62 (45-51)	<0.0001	22 (15-30)	0.57	16 (9-23)	<0.0001	16 (8-22)	0.002	8 (3-13)	<0.0001	32 (24-41)	0.6	23 (16-31)	0.03
No	48 (53-64)		20 (17-23)		32 (29-35)		39 (36-42)		23 (20-25)		31 (28-34)		32 (29-35)	
7q- vs -7														
7q-	44 (38-49)	0.005	21 (17-26)	0.72	35 (30-41)	0.004	42 (36-47)	0.015	26 (21-31)	0.002	28 (23-33)	0.16	32 (26-37)	0.65
-7	52 (49-56)		20 (17-23)		28 (25-32)		34 (31-38)		19 (16-22)		32 (29-35)		31 (27-34)	

Abbreviations: CK: complex karyotype; MK: monosomal karyotype; Abn(5q): monosomy 5 or deletion 5q; Inv(3): abnormalities of 3q26 (inv(3)/t(3;3); abn(17p): 17p abnormalities; 7q-: deletion 7q; -7: monosomy 7; RI: relapse incidence; 2y: 2 years; CI: confidence interval; p: p-value; NRM: non-relapse mortality; LFS: leukemia-free survival; OS: overall survival; GRFS: graft-versus-host disease and relapse-free survival; aGVHD: acute graft-versus-host disease; cGvHD: chronic graft-versus-host-disease.

Table 3
Multivariate analysis using a Cox proportional hazard model in the entire cohort for RI, NRM, OS and LFS.
Only variables with a p<0.05 in univariate analysis were included in this analysis

	RI			NRM			LFS			OS			GRFS		
	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI
<i>Age (per 10 year)</i>	0.48	0.97	0.9-1.05	0.5	1.04	0.92-1.18	0.73	0.99	0.92-1.06	0.79	1.01	0.94-1.08	0.86	0.99	0.93-1.06
<i>MUD vs MSD</i>	0.08	0.83	0.67-1.02	0.005	1.6	1.15-2.21	0.86	1.02	0.85-1.21	0.33	1.09	0.91-1.31	0.91	0.99	0.84-1.17
<i>Year of SCT</i>	0.19	0.99	0.96-1.01	0.089	0.97	0.94-1.01	0.05	0.98	0.96-1.00	0.09	0.98	0.96-1.00	0.054	0.98	0.97-1.00
<i>Secondary AML vs de novo</i>	0.73	0.96	0.76-1.21	0.00006	1.86	1.37-2.52	0.05	1.2	1.00-1.44	0.01	1.28	1.06-1.54	0.048	1.20	1.00-1.43
<i>CR2/3 vs CR1</i>	0.6	1.14	0.71-1.82	0.0004	2.39	1.47-3.89	0.009	1.56	1.12-2.18	0.008	1.60	1.13-2.27	0.027	1.45	1.04-2.01
<i>Active disease vs CR1</i>	<0.00001	1.69	1.39-2.06	0.0057	1.53	1.13-2.06	<0.00001	1.64	1.39-1.93	<0.00001	1.63	1.38-1.93	<0.00001	1.51	1.29-1.77
<i>KPS≥80%</i>	0.47	0.87	0.59-1.27	0.00001	0.37	0.24-0.56	0.001	0.62	0.47-0.83	0.00007	0.55	0.42-0.74	0.002	0.65	0.49-0.86
<i>RIC vs MAC</i>	0.2	1.14	0.93-1.39	0.17	1.24	0.91-1.68	0.04	1.19	1.01-1.4	0.1	1.15	0.97-1.36	0.06	1.17	0.99-1.37
<i>Female to Male</i>	0.93	0.99	0.78-1.26	0.13	1.31	0.93-1.85	0.45	1.08	0.89-1.31	0.33	1.11	0.9-1.35	0.16	1.14	0.95-1.38
<i>In vivo TCD</i>	0.94	1.01	0.82-1.24	0.15	0.8	0.58-1.09	0.4	0.93	0.78-1.11	0.32	0.91	0.76-1.09	0.007	0.80	0.68-0.94
<i>Patient CMV+</i>	0.35	0.91	0.75-1.11	0.84	1.03	0.76-1.4	0.5	0.95	0.8-1.11	0.48	0.94	0.79-1.12	0.19	0.9	0.77-1.05
<i>Donor CMV+</i>	0.5	1.07	0.88-1.29	0.86	0.97	0.73-1.31	0.64	1.04	0.89-1.22	0.46	1.07	0.9-1.13	0.71	0.97	0.83-1.13
<i>CK</i>	0.93	1.01	0.8-1.27	0.19	1.26	0.89-1.78	0.38	1.09	0.9-1.32	0.07	1.2	0.98-1.46	0.098	1.17	0.97-1.41
<i>MK</i>	0.007	1.39	1.1-1.77	0.85	0.97	0.67-1.39	0.04	1.24	1.01-1.51	0.08	1.2	0.98-1.48	0.01	1.27	1.05-1.55
<i>-5/5q-</i>	0.009	1.4	1.09-1.80	0.85	1.04	0.69-1.57	0.02	1.28	1.03-1.59	0.019	1.3	1.05-1.62	0.33	1.11	0.90-1.37
<i>abn(17p)</i>	0.003	1.55	1.16-2.07	0.35	1.27	0.77-2.07	0.003	1.46	1.14-1.87	0.007	1.4	1.11-1.85	0.016	1.35	1.06-1.73
<i>inv(3)</i>	0.0003	1.78	1.3-2.42	0.73	1.11	0.63-1.95	0.001	1.57	1.2-2.05	0.005	1.5	1.13-1.99	0.006	1.44	1.11-1.86

Abbreviations: HR: hazard ratio; CI: confidence interval; RI: relapse incidence; MUD: matched unrelated donor; MSD: matched sibling donor; SCT: stem cell transplantation; AML: acute myeloid leukemia; CR2/3: subsequent remission; CR1: first remission; KPS: Karnofsky performance status; RIC: reduced-intensity conditioning; MAC: myeloablative conditioning; TCD: T-cell depletion; CMV: cytomegalovirus; CK: complex karyotype; MK: monosomal karyotype; -5/5q-: monosomy 5 or deletion 5q; abn(17p): 17p abnormalities; inv(3): inversion of chromosome 3; NRM: non-relapse mortality; LFS: leukemia-free survival; OS: overall survival; GRFS: graft-versus-host and relapse-free survival.

Table 4
Multivariate analysis using a Cox proportional hazard model including cytogenetic subgroups for RI, NRM, LFS, OS and GRFS.

	RI			NRM			LFS			OS			GRFS		
	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI
<i>Age (per 10 year)</i>	0.55	0.98	0.9-1.06	0.53	1.04	0.92-1.18	0.78	0.99	0.93-1.06	0.79	1.01	0.94-1.08	0.84	0.99	0.93-1.06
<i>MUD vs MSD</i>	0.06	0.82	0.67-1.01	0.004	1.61	1.16-2.24	0.98	1.00	0.84-1.19	0.39	1.08	0.9-1.3	0.8	0.98	0.83-1.15
<i>Year of SCT</i>	0.2	0.99	0.96-1.01	0.09	0.97	0.94-1.01	0.05	0.98	0.96-1.00	0.11	0.98	0.96-1.00	0.05	0.98	0.97-1.00
<i>Secondary AML vs de novo</i>	0.7	0.96	0.76-1.21	0.00005	1.87	1.38-2.54	0.06	1.2	1.00-1.44	0.01	1.27	1.05-1.53	0.09	1.17	0.98-1.4
<i>CR2/3 vs CR1</i>	0.58	1.14	0.71-1.82	0.0005	2.37	1.46-3.84	0.009	1.56	1.12-2.18	0.012	1.56	1.1-2.21	0.04	1.42	1.03-1.97
<i>Active disease vs CR1</i>	<0.00001	1.7	1.4-2.07	0.004	1.55	1.15-2.1	<0.00001	1.65	1.40-1.95	<0.00001	1.63	1.38-1.93	<0.00001	1.52	1.3-1.77
<i>CR1 ≥80%</i>	0.41	0.85	0.58-1.25	<0.00001	0.36	0.23-0.56	0.0009	0.62	0.47-0.82	0.00007	0.56	0.42-0.74	0.002	0.64	0.49-0.85
<i>RIC vs MAC</i>	0.26	1.12	0.92-1.37	0.16	1.25	0.92-1.69	0.06	1.18	1.00-1.39	0.14	1.14	0.96-1.35	0.07	1.16	1.00-1.37
<i>Female to Male</i>	0.87	1.02	0.8-1.3	0.1	1.34	0.95-1.88	0.31	1.11	0.91-1.35	0.2	1.14	0.93-1.39	0.11	1.17	0.97-1.41
<i>In vivo TCD</i>	0.95	1.01	0.82-1.24	0.12	0.78	0.57-1.07	0.41	0.93	0.78-1.11	0.36	0.92	0.77-1.1	0.007	0.8	0.68-0.94
<i>Patient CMV+</i>	0.33	0.91	0.75-1.1	0.78	1.04	0.77-1.41	0.52	0.95	0.8-1.12	0.53	0.95	0.8-1.12	0.25	0.91	0.78-1.07
<i>Donor CMV+</i>	0.41	1.08	0.9-1.31	0.83	0.97	0.72-1.3	0.59	1.05	0.89-1.23	0.44	1.07	0.9-1.26	0.73	0.97	0.84-1.13
<i>7± CK (reference)</i>		1			1			1			1			1	
<i>-7± CK</i>	0.006	1.54	1.13-2.09	0.53	0.88	0.6-1.3	0.05	1.26	1.00-1.60	0.19	1.18	0.92-1.51	0.06	1.24	0.99-1.55
<i>ML group</i>	0.00003	2.02	1.45-2.82	0.47	1.17	0.76-1.82	0.0002	1.66	1.28-2.16	0.0008	1.6	1.22-2.1	0.00003	1.70	1.33-2.19
<i>-5/5q- group</i>	<0.00001	2.62	1.88-2.68	0.59	1.14	0.71-1.84	<0.00001	2.00	1.52-2.61	<0.00001	2.0	1.51-2.64	<0.00001	1.94	1.5-2.5
<i>Abn(17p) group</i>	<0.0001	3.76	2.67-5.3	0.12	1.48	0.9-2.44	<0.00001	2.78	2.11-3.67	<0.00001	2.74	2.05-3.65	<0.00001	2.47	1.9-3.22
<i>Inv(3) group</i>	<0.0001	3.47	2.42-4.97	0.72	1.11	0.63-1.98	<0.00001	2.45	1.82-3.29	<0.00001	2.21	1.63-3.00	<0.00001	2.27	1.71-3.01

Abbreviations: HR: hazard ratio; CI: confidence interval; MUD: matched unrelated donor; MSD: matched sibling donor; SCT: stem cell transplantation; AML: acute myeloid leukemia; CR2/3: subsequent remission; CR1: first remission; KPS: Karnofsky's performance status; RIC: reduced-intensity conditioning; MAC: myeloablative conditioning regimen; TCD: T-cell depletion; CMV: cytomegalovirus; RI: relapse incidence; abn(17p): abnormalities of chromosome 17p; CK: complex karyotype; MK: monosomal karyotype; -5/5q-: monosomy 5 or deletion 5q; inv(3) : inversion of chromosome 3; NRM: non-relapse mortality; LFS: leukemia-free survival; OS: overall survival; GRFS: graft-versus-host and relapse-free survival.